サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159261

体軸性脊椎関節炎治療薬の世界市場（2022年～2028年）

Axial Spondyloarthritis Drug Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 120 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
体軸性脊椎関節炎治療薬の世界市場（2022年～2028年）
出版日: 2022年09月25日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の体軸性脊椎関節炎治療薬の市場規模は、予測期間中に4.1%のCAGRで拡大すると予測されています。予測期間中、同市場は、承認されたバイオシミラー数の増加や軸索脊椎関節炎の有病率の上昇によって牽引されるとみられています。

当レポートでは、世界の体軸性脊椎関節炎治療薬市場について調査し、市場の概要とともに、タイプ別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

第3章 競合情勢

  • 主要企業分析
    • AstraZeneca Plc.
    • Eli Lilly and Co.
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Panacea Biotec Ltd
  • 主要戦略分析
  • COVID-19が主要参入企業に与える影響

第4章 市場セグメンテーション

  • 世界の体軸性脊椎関節炎治療薬市場、タイプ別
    • セルトリズマブペゴル
    • エタネルセプトのバイオシミラー
    • イセキズマブ
    • その他（セクキヌマブ）
  • 世界の体軸性脊椎関節炎治療薬市場、流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第5章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Abbott
  • AbbVie Inc.
  • Amgen Inc.
  • GlaxoSmithKLine Plc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • KYOCERA Corp.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.
図表

LIST OF TABLES

  • 1. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL CERTOLIZUMAB PEGOL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL ETANERCEPT BIOSIMILAR AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL IXEKIZUMAB AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL OTHERS DRUG IN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 7. GLOBAL HOSPITAL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL RETAIL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL ONLINE PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 14. EUROPEAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. EUROPEAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 16. EUROPEAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET, 2022-2028 (%)
  • 4. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL CERTOLIZUMAB PEGOL ANTI-INFLAMMATORY DRUGS (NSAID) AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL ETANERCEPT BIOSIMILAR AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL IXEKIZUMAB AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL OTHERS DRUG IN AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
  • 10. GLOBAL HOSPITAL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL RETAIL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL ONLINE PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. US AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. CANADA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. UK AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. FRANCE AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. GERMANY AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. ITALY AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. SPAIN AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF EUROPE AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. INDIA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. CHINA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. JAPAN AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. SOUTH KOREA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026366

Global Axial Spondyloarthritis Drug Market Size, Share & Trends Analysis Report By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2022-2028)

The global axial spondyloarthritis drug market is anticipated to grow at a substantial CAGR of 4.1% during the forecast period. During the forecast period, the global axial spondyloarthritis drug market is expected to be driven by an increase in the number of approved biosimilars and an increase in the prevalence of axial spondyloarthritis. Furthermore, the increase in research and development activities, and the high unmet need for existing treatment, will benefit the axial spondyloarthritis drug market in the forecast year. The high cost of biologics, on the other hand, is expected to limit the global axial spondyloarthritis drug market.

The global axial spondyloarthritis drug market is segmented based on type and distribution channel. Based on the type, the market is sub-segmented into the certolizumab pegol, etanercept biosimilar, ixekizumab, and others. Based on the distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Etanercept Biosimilar is anticipated to have a significant market share in the market. Etanercept Biosimilar is a biological medication that works by suppressing a soluble inflammatory cytokine called tumor necrosis factor (TNF). Etanercept is used to treat rheumatoid, juvenile rheumatoid, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, among other conditions.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds a significant share in the market after the Asia Pacific. The region's dominance is due to a higher percentage of total income spent on health care compared to other economies, adequate reimbursement, along with widespread awareness.

The major companies serving the global axial spondyloarthritis drug market include AstraZeneca Plc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Novartis AG, Panacea Biotec Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2020, Novartis AG announced that Secukinumab, an IL-17a inhibitor, had been approved by the US Food and Drug Administration for the treatment of psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

Research Methodology

The market study of the global axial spondyloarthritis drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Axial Spondyloarthritis Drug Market Research and Analysis by Type

2. Global Axial Spondyloarthritis Drug Market Research and Analysis by Distribution Channel

The Report Covers:

  • Comprehensive Research Methodology of the global axial spondyloarthritis drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global axial spondyloarthritis drug market.
  • Insights about market determinants that are stimulating the global axial spondyloarthritis drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Axial spondyloarthritis drug Market
  • Recovery Scenario of Global Axial spondyloarthritis drug Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. AstraZeneca Plc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Eli Lilly and Co.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Johnson & Johnson Services, Inc.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Novartis AG
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Panacea Biotec Ltd.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Axial Spondyloarthritis Drug Market by Type
    • 4.1.1. Certolizumab Pegol
    • 4.1.2. Etanercept Biosimilar
    • 4.1.3. Ixekizumab
    • 4.1.4. Others (Secukinumab)

4.3.Global Axial Spondyloarthritis Drug Market by Distribution Channel

4.3.1. Hospital Pharmacies

4.3.2 Retail Pharmacies

4.3.3 Online Pharmacies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott
  • 6.2. AbbVie Inc.
  • 6.3. Amgen Inc.
  • 6.4. GlaxoSmithKLine Plc.
  • 6.5. Kyowa Kirin Co., Ltd.
  • 6.6. Merck & Co. Inc.
  • 6.7. Pfizer Inc.
  • 6.8. Sandoz International GmbH
  • 6.9. KYOCERA Corp.
  • 6.10. Sun Pharmaceutical Industries Ltd.
  • 6.11. UCB S.A.